Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Titel:
Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN
Auteur:
Nicholls, Stephen J. Nelson, Adam J. Ditmarsch, Marc Kastelein, John J.P. Ballantyne, Christie M. Ray, Kausik K. Navar, Ann Marie Nissen, Steven E. Goldberg, Anne C. Brunham, Liam R. Curcio, Danielle Wuerdeman, Erin Neild, Annie Kling, Douglas Hsieh, Andrew Dicklin, Mary R. Ference, Brian A. Laufs, Ulrich Banach, Maciej Mehran, Roxana Catapano, Alberico L. Davidson, Michael H.